{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T05:25:16Z","timestamp":1731043516522,"version":"3.28.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00108-024-01764-6","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T09:02:56Z","timestamp":1724835776000},"page":"1092-1098","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Zosterimpfung","Zoster vaccination"],"prefix":"10.1007","volume":"65","author":[{"given":"Marco","family":"Krasselt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning","family":"Trawinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"L\u00fcbbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"1764_CR1","unstructured":"RKI-Ratgeber RKI (2017) Windpocken (Varizellen), G\u00fcrtelrose (HZ). https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Merkblaetter\/Ratgeber_Varizellen.html;. Zugegriffen: 2. Mai 2024"},{"key":"1764_CR2","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/S2666-7568(22)00039-3","volume":"3","author":"JF Mbinta","year":"2022","unstructured":"Mbinta\u00a0JF, Nguyen\u00a0BP, Awuni\u00a0PMA et\u00a0al (2022) Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a\u00a0systematic review and meta-analysis. Lancet Healthy Longev 3:e263\u2013e275. https:\/\/doi.org\/10.1016\/S2666-7568(22)00039-3","journal-title":"Lancet Healthy Longev"},{"key":"1764_CR3","doi-asserted-by":"publisher","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","volume":"4","author":"K Kawai","year":"2014","unstructured":"Kawai\u00a0K, Gebremeskel\u00a0BG, Acosta\u00a0CJ (2014) Systematic review of incidence and complications of herpes zoster: towards a\u00a0global perspective. BMJ Open 4:e4833. https:\/\/doi.org\/10.1136\/bmjopen-2014-004833","journal-title":"BMJ Open"},{"key":"1764_CR4","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1038\/nrdp.2015.16","volume":"1","author":"AA Gershon","year":"2015","unstructured":"Gershon\u00a0AA, Breuer\u00a0J, Cohen\u00a0JI et\u00a0al (2015) Varicella zoster virus infection. Nat Rev Dis Primers 1:15016. https:\/\/doi.org\/10.1038\/nrdp.2015.16","journal-title":"Nat Rev Dis Primers"},{"key":"1764_CR5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40121-024-00924-3","volume":"13","author":"R Parikh","year":"2024","unstructured":"Parikh\u00a0R, Yousefi\u00a0M, Curran\u00a0D et\u00a0al (2024) The impact of the COVID-19 pandemic on the incidence of herpes zoster: a\u00a0narrative literature review. Infect Dis Ther 13:447\u2013461. https:\/\/doi.org\/10.1007\/s40121-024-00924-3","journal-title":"Infect Dis Ther"},{"key":"1764_CR6","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","volume":"385","author":"N Barda","year":"2021","unstructured":"Barda\u00a0N, Dagan\u00a0N, Ben-Shlomo\u00a0Y et\u00a0al (2021) Safety of the BNT162b2 mRNA Covid-19 vaccine in a\u00a0nationwide setting. N\u00a0Engl J Med 385:1078\u20131090. https:\/\/doi.org\/10.1056\/NEJMoa2110475","journal-title":"N Engl J Med"},{"key":"1764_CR7","doi-asserted-by":"publisher","first-page":"1130090","DOI":"10.3389\/fneur.2023.1130090","volume":"14","author":"LS Abbuehl","year":"2023","unstructured":"Abbuehl\u00a0LS, Hofmann\u00a0E, Hakim\u00a0A et\u00a0al (2023) Can we forecast poor outcome in herpes simplex and varicella zoster encephalitis? A\u00a0narrative review. Front Neurol 14:1130090. https:\/\/doi.org\/10.3389\/fneur.2023.1130090","journal-title":"Front Neurol"},{"key":"1764_CR8","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s13365-020-00872-x","volume":"26","author":"C Corral","year":"2020","unstructured":"Corral\u00a0C, Quereda\u00a0C, Muriel\u00a0A et\u00a0al (2020) Clinical spectrum and prognosis of neurological complications of reactivated varicella-zoster infection: the role of immunosuppression. J\u00a0Neurovirol 26:696\u2013703. https:\/\/doi.org\/10.1007\/s13365-020-00872-x","journal-title":"J Neurovirol"},{"key":"1764_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.25646\/11892.3","volume-title":"Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) beim Robert Koch-Institut 2024","author":"RKI. St\u00e4ndige Impfkommission (STIKO)","year":"2024","unstructured":"RKI. St\u00e4ndige Impfkommission (STIKO) (2024) Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) beim Robert Koch-Institut 2024 Bd. 4, S\u00a01\u201372 https:\/\/doi.org\/10.25646\/11892.3"},{"key":"1764_CR10","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham\u00a0AL, Lal\u00a0H, Kovac\u00a0M et\u00a0al (2016) Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N\u00a0Engl J Med 375:1019\u20131032. https:\/\/doi.org\/10.1056\/NEJMoa1603800","journal-title":"N Engl J Med"},{"key":"1764_CR11","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal\u00a0H, Cunningham\u00a0AL, Godeaux\u00a0O et\u00a0al (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N\u00a0Engl J Med 372:2087\u20132096. https:\/\/doi.org\/10.1056\/NEJMoa1501184","journal-title":"N Engl J Med"},{"key":"1764_CR12","unstructured":"EMA (2020) Shingrix. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/shingrix;. Zugegriffen: 2. Mai 2024"},{"key":"1764_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1001\/jama.2019.9053","volume":"322","author":"A Bastidas","year":"2019","unstructured":"Bastidas\u00a0A, de la Serna\u00a0J, El Idrissi\u00a0M et\u00a0al (2019) Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a\u00a0randomized clinical trial. JAMA 322:123\u2013133. https:\/\/doi.org\/10.1001\/jama.2019.9053","journal-title":"JAMA"},{"key":"1764_CR14","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","volume":"19","author":"AF Dagnew","year":"2019","unstructured":"Dagnew\u00a0AF, Ilhan\u00a0O, Lee\u00a0WS et\u00a0al (2019) Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a\u00a0phase\u00a03, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis 19:988\u20131000. https:\/\/doi.org\/10.1016\/S1473-3099(19)30163-X","journal-title":"Lancet Infect Dis"},{"key":"1764_CR15","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1002\/art.38804","volume":"66","author":"C Rondaan","year":"2014","unstructured":"Rondaan\u00a0C, de Haan\u00a0A, Horst\u00a0G et\u00a0al (2014) Altered cellular and humoral immunity to varicella-zoster virus in patients with autoimmune diseases. Arthritis Rheumatol 66:3122\u20133128. https:\/\/doi.org\/10.1002\/art.38804","journal-title":"Arthritis Rheumatol"},{"key":"1764_CR16","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3899\/jrheum.220986","volume":"50","author":"D Singer","year":"2023","unstructured":"Singer\u00a0D, Thompson-Leduc\u00a0P, Poston\u00a0S et\u00a0al (2023) Incidence of herpes zoster in patients with rheumatoid arthritis in the United States: a\u00a0retrospective cohort study. J\u00a0Rheumatol 50:873\u2013880. https:\/\/doi.org\/10.3899\/jrheum.220986","journal-title":"J Rheumatol"},{"key":"1764_CR17","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.39670","volume":"68","author":"H Yun","year":"2016","unstructured":"Yun\u00a0H, Yang\u00a0S, Chen\u00a0L et\u00a0al (2016) Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol 68:2328\u20132337. https:\/\/doi.org\/10.1002\/art.39670","journal-title":"Arthritis Rheumatol"},{"key":"1764_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001235","author":"TR Riley","year":"2021","unstructured":"Riley\u00a0TR, George\u00a0MD (2021) Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2020-001235","journal-title":"RMD Open"},{"key":"1764_CR19","doi-asserted-by":"publisher","first-page":"e014032","DOI":"10.1136\/bmjopen-2016-014032","volume":"7","author":"TL Liao","year":"2017","unstructured":"Liao\u00a0TL, Chen\u00a0YM, Liu\u00a0HJ et\u00a0al (2017) Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a\u00a0case-control study in Asia. BMJ Open 7:e14032. https:\/\/doi.org\/10.1136\/bmjopen-2016-014032","journal-title":"BMJ Open"},{"key":"1764_CR20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jinf.2022.01.003","volume":"84","author":"S Chawki","year":"2022","unstructured":"Chawki\u00a0S, Vilcu\u00a0AM, Etienne\u00a0C et\u00a0al (2022) Incidence of complications of herpes zoster in individuals on immunosuppressive therapy: a\u00a0register-based population study. J\u00a0Infect 84:531\u2013536. https:\/\/doi.org\/10.1016\/j.jinf.2022.01.003","journal-title":"J Infect"},{"key":"1764_CR21","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1186\/s12879-020-05648-6","volume":"20","author":"C Munoz-Quiles","year":"2020","unstructured":"Munoz-Quiles\u00a0C, Lopez-Lacort\u00a0M, Diez-Domingo\u00a0J et\u00a0al (2020) Herpes zoster risk and burden of disease in immunocompromised populations: a\u00a0population-based study using health system integrated databases, 2009\u20132014. BMC Infect Dis 20:905. https:\/\/doi.org\/10.1186\/s12879-020-05648-6","journal-title":"BMC Infect Dis"},{"key":"1764_CR22","doi-asserted-by":"publisher","first-page":"e020528","DOI":"10.1136\/bmjopen-2017-020528","volume":"8","author":"EA Yanni","year":"2018","unstructured":"Yanni\u00a0EA, Ferreira\u00a0G, Guennec\u00a0M et\u00a0al (2018) Burden of herpes zoster in 16 selected immunocompromised populations in England: a\u00a0cohort study in the clinical practice research datalink 2000\u20132012. BMJ Open 8:e20528. https:\/\/doi.org\/10.1136\/bmjopen-2017-020528","journal-title":"BMJ Open"},{"key":"1764_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1212\/WNL.0000000000002808","volume":"87","author":"HJ Forbes","year":"2016","unstructured":"Forbes\u00a0HJ, Bhaskaran\u00a0K, Thomas\u00a0SL et\u00a0al (2016) Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: a\u00a0cohort study. Neurology 87:94\u2013102. https:\/\/doi.org\/10.1212\/WNL.0000000000002808","journal-title":"Neurology"},{"key":"1764_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11040760","author":"M Krasselt","year":"2023","unstructured":"Krasselt\u00a0M, Wagner\u00a0U, Seifert\u00a0O (2023) Influenza, pneumococcal and herpes zoster vaccination rates in patients with autoimmune inflammatory rheumatic diseases. Vaccines. https:\/\/doi.org\/10.3390\/vaccines11040760","journal-title":"Vaccines"},{"key":"1764_CR25","unstructured":"SIKO. S\u00e4chsische Impfkommission (SIKO) (2024) Empfehlungen zur Durchf\u00fchrung von Schutzimpfungen im Freistaat Sachsen. https:\/\/www.slaek.de\/media\/dokumente\/patient\/gesundheitsinformationen\/impfen\/E1_Rev2024_final.pdf;. Zugegriffen: 15. Mai 2024"},{"key":"1764_CR26","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00103-019-02905-1","volume":"62","author":"N Wagner","year":"2019","unstructured":"Wagner\u00a0N, Assmus\u00a0F, Arendt\u00a0G et\u00a0al (2019) Anwendungshinweise zu den von der St\u00e4ndigen Impfkommission empfohlenen Impfungen. (IV)\u00a0Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entz\u00fcndlichen Erkrankungen und unter immunmodulatorischer Therapie. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 62:494\u2013515. https:\/\/doi.org\/10.1007\/s00103-019-02905-1","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"1764_CR27","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/acr.25045","volume":"75","author":"AR Bass","year":"2022","unstructured":"Bass\u00a0AR, Chakravarty\u00a0E, Akl\u00a0EA et\u00a0al (2022) American college of rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Care Res 75:449\u2013464. https:\/\/doi.org\/10.1002\/acr.25045","journal-title":"Arthritis Care Res"},{"key":"1764_CR28","unstructured":"ACIP (2021) Clinical considerations for use of recombinant zoster vaccine (RZV, Shingrix) in immunocompromised adults aged \u2265\u202f19 years. https:\/\/www.cdc.gov\/vaccines\/vpd\/shingles\/hcp\/immunocompromised-adults.html;. Zugegriffen: 13. Mai 2024"},{"key":"1764_CR29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.17886\/EpiBull-2017-059.2","volume":"50","author":"RKI. St\u00e4ndige Impfkommission (STIKO)","year":"2018","unstructured":"RKI. St\u00e4ndige Impfkommission (STIKO) (2018) Wissenschaftliche Begr\u00fcndung zur Empfehlung einer Impfung mit dem Herpes zoster-subunit-Totimpfstoff. Epid Bull 50:541\u2013567. https:\/\/doi.org\/10.17886\/EpiBull-2017-059.2","journal-title":"Epid Bull"},{"key":"1764_CR30","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1093\/rheumatology\/keaa424","volume":"60","author":"AF Dagnew","year":"2021","unstructured":"Dagnew\u00a0AF, Rausch\u00a0D, Herve\u00a0C et\u00a0al (2021) Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a\u00a0pooled post hoc analysis on two parallel randomized trials. Rheumatology 60:1226\u20131233. https:\/\/doi.org\/10.1093\/rheumatology\/keaa424","journal-title":"Rheumatology"},{"key":"1764_CR31","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1080\/21645515.2019.1627818","volume":"15","author":"L Oostvogels","year":"2019","unstructured":"Oostvogels\u00a0L, Heineman\u00a0TC, Johnson\u00a0RW et\u00a0al (2019) Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a\u00a0pooled post-hoc analysis of two parallel randomized trials. Hum Vaccin Immunother 15:2865\u20132872. https:\/\/doi.org\/10.1080\/21645515.2019.1627818","journal-title":"Hum Vaccin Immunother"},{"key":"1764_CR32","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/acr2.11150","volume":"2","author":"E Stevens","year":"2020","unstructured":"Stevens\u00a0E, Weinblatt\u00a0ME, Massarotti\u00a0E et\u00a0al (2020) Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a\u00a0single center\u2019s experience with 400 patients. ACR Open Rheumatol 2:357\u2013361. https:\/\/doi.org\/10.1002\/acr2.11150","journal-title":"ACR Open Rheumatol"},{"key":"1764_CR33","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.1093\/rheumatology\/keab139","volume":"60","author":"T Lenfant","year":"2021","unstructured":"Lenfant\u00a0T, Jin\u00a0Y, Kirchner\u00a0E et\u00a0al (2021) Safety of recombinant zoster vaccine: a\u00a0retrospective study of 622 rheumatology patients. Rheumatology 60:5149\u20135157. https:\/\/doi.org\/10.1093\/rheumatology\/keab139","journal-title":"Rheumatology"},{"key":"1764_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24086967","author":"V Venerito","year":"2023","unstructured":"Venerito\u00a0V, Stefanizzi\u00a0P, Cantarini\u00a0L et\u00a0al (2023) Immunogenicity and safety of adjuvanted recombinant zoster vaccine in rheumatoid arthritis patients on anti-cellular biologic agents or JAK inhibitors: a\u00a0prospective observational study. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24086967","journal-title":"Int J Mol Sci"},{"key":"1764_CR35","doi-asserted-by":"publisher","first-page":"SI180","DOI":"10.1093\/rheumatology\/keac089","volume":"61","author":"M Krasselt","year":"2022","unstructured":"Krasselt\u00a0M, Wagner\u00a0U, Nguyen\u00a0P et\u00a0al (2022) Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions. Rheumatology 61:SI180\u2013SI188. https:\/\/doi.org\/10.1093\/rheumatology\/keac089","journal-title":"Rheumatology"},{"key":"1764_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead552","author":"H Kallmark","year":"2023","unstructured":"Kallmark\u00a0H, Bergstrom\u00a0T, Nagel\u00a0J et\u00a0al (2023) Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/kead552","journal-title":"Rheumatology"},{"key":"1764_CR37","doi-asserted-by":"publisher","first-page":"6205","DOI":"10.1016\/j.vaccine.2020.07.049","volume":"38","author":"E Racine","year":"2020","unstructured":"Racine\u00a0E, Gilca\u00a0V, Amini\u00a0R et\u00a0al (2020) A\u00a0systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18\u201349\u00a0year old patients. Vaccine 38:6205\u20136214. https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.049","journal-title":"Vaccine"},{"key":"1764_CR38","unstructured":"RKI (2021) G\u00fcrtelrose (Herpes zoster): Antworten auf h\u00e4ufig gestellte Fragen zu Erkrankung und Impfung. https:\/\/www.rki.de\/SharedDocs\/FAQ\/Herpes_zoster\/FAQ-Liste.html?nn=2375548;. Zugegriffen: 2. Mai 2024"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01764-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01764-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01764-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T18:01:59Z","timestamp":1731002519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01764-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1764"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01764-6","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"type":"print","value":"2731-7080"},{"type":"electronic","value":"2731-7099"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"assertion":[{"value":"11 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Krasselt hat Honorare f\u00fcr Vortragst\u00e4tigkeiten und Reisekostenerstattungen von GSK erhalten. H.\u00a0Trawinski und C.\u00a0L\u00fcbbert geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}